GoodRx Holdings (NASDAQ:GDRX) has announced significant changes to its board of directors with the appointment of Ian T. Clark as a Class III director, effective July 8, 2024.

Clark, who has an extensive background with over 35 years in the pharmaceutical and healthcare industries, steps into the role following the resignation of Stephen LeSieur.

Clark is notably recognized for his tenure as CEO of Genentech.

In his new role at GoodRx, he will lead the company’s newly formed Innovation Committee and will also serve on the Nominating and Corporate Governance Committee.

In recognition of his appointment, Clark has been awarded Restricted Stock Units (RSUs) valued at $420,000, along with additional compensations.